Drug class in one race
Dopamine D2/D3 and serotonin 5-HT1A receptor drugs for Schizophrenia
6 tracked Dopamine D2/D3 and serotonin 5-HT1A receptor drugs in the Schizophrenia race. The class explanation lives on the Dopamine D2/D3 and serotonin 5-HT1A receptor page; the full indication pipeline across every mechanism is on the Schizophrenia page.
5 approved / phase 41 Phase 1
Head-to-head evidence: Aripiprazole (Abilify) vs Aripiprazole (Abilify Maintena) · Aripiprazole (Abilify Maintena) vs Aripiprazole lauroxil (Aristada Initio) · Aripiprazole (Abilify Maintena) vs Aripiprazole lauroxil (Aristada) · Aripiprazole (Abilify Maintena) vs Brexpiprazole (Rexulti) · Aripiprazole (Abilify Maintena) vs Brexpiprazole long-acting injection (Kelun) · Aripiprazole (Abilify) vs Aripiprazole lauroxil (Aristada Initio)